Review
Published · Updated · 1 min read
HPV vaccination up to age 26 in France: a report in the Egora overview
What it means for practice
The report concerns catch-up HPV vaccination. Before using these findings in practice, verify the primary study and the conditions of the vaccination expansion in France.
Summary
The abstract of the Egora overview describes the expansion of human papillomavirus (HPV) vaccination with GARDASIL® 9 in France to individuals up to 26 years old. The stated aim is to reduce cervical cancer incidence. This is a report about French practice, not a presentation of recommendations for Ukraine.
The abstract also refers to a Swedish study reporting a 62% reduction in cervical cancer cases with catch-up vaccination. The ages of participants in the Swedish study are not provided; the age limit stated for France cannot automatically be applied to this study population.
The available description does not provide the study design, sample size, comparator characteristics, follow-up duration or estimates of statistical uncertainty. It therefore does not allow a detailed assessment of the reliability of the finding or its applicability to a particular clinical situation. The vaccination schedule, eligibility criteria and safety data are also not provided in the abstract.
Source
-
Egora - La voix des médecins N°444.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
